Boston Scientific invests $1.5B for 34% stake in MiRus

Boston Scientific acquired a 34% equity stake in MiRus for $1.5 billion, with an option to acquire the rest of its TAVR business for up to $3 billion in additional payments.

“We believe the distinctive design and impressive early clinical results of the SIEGEL valve may set it apart from currently available technology”medtechdive.com

• 1 source
• medtechdive.comBoston Scientific buys $1.5B stake in TAVR developer MiRus | MedTech DiveSusan KellyMay 18, 2026

Summarized from public sources; check the original articles before acting on it.